Streetbeat News

GNPX

Genprex, Inc.

https://www.genprex.com

Industry

Biotechnology

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Genprex has been granted a patent in Singapore for its Reqorsa gene therapy in combination with PD-1 antibodies, extending protection through 2037. This expands on previously granted patents covering the use of REQORSA with immune checkpoint inhibitors.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:33 pm

Genprex shares are trading higher after the company provided 2024 updates.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 1:10 pm

Genprex has issued a letter providing a 2024 update, highlighting multiple clinical development milestones and ongoing patient treatment in three lung cancer clinical trials.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:35 pm

The article highlights significant intraday movements in health care stocks on Friday. Notable gainers include Novo Integrated Sciences (NVOS), Anebulo Pharmaceuticals (ANEB), Annovis Bio (ANVS), Vaccinex (VCNX), Genprex (GNPX), and Purple Biotech (PPBT). Significant losers include Calidi Biotherapeutics (CLDI), Summit Therapeutics (SMMT), Heart Test Laboratories (HSCS), Humacyte (HUMA), Concord Medical Services (CCM), and Pulse Biosciences (PLSE).

Portfolio Pulse from Benzinga Insights

May 31, 2024 | 4:31 pm

HC Wainwright & Co. has reiterated its Buy rating on Genprex (NASDAQ:GNPX) and maintained a $10 price target, as stated by analyst Yi Chen.

Portfolio Pulse from Benzinga Newsdesk

May 17, 2024 | 12:18 pm

HC Wainwright & Co. has reiterated its Buy rating on Genprex (NASDAQ:GNPX) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 3:28 pm

Genprex has announced the appointment of Jose A. Moreno Toscano as the new Chairman of its Board of Directors. This strategic move aims to leverage Toscano's extensive experience in the pharmaceutical industry to guide Genprex's future growth and development.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:39 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Tevogen Bio Holdings (TVGN) led the gainers with a 75.3% increase, while Processa Pharma (PCSA) experienced the largest drop among the losers, falling 15.6%. Other notable movers included Cryo-Cell International (CCEL) and Moleculin Biotech (MBRX) with substantial gains, and SCWorx (WORX) and Nuwellis (NUWE) with notable losses.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 12:06 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Genprex (NASDAQ:GNPX) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 10:33 am

Genprex is expanding its clinical trial sites for the Acclaim-3 clinical study, which tests Reqorsa Therapy in combination with Tecentriq for treating small cell lung cancer. This expansion is in collaboration with a large network of community-based oncology practices. The Acclaim-3 study has received support from the FDA in the form of Orphan Drug and Fast Track Designations.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.